Medical staff plagued by insomnia during pandemic
Article written by Gary Finnegan More than a third of medical staff suffered insomnia during the COVID-19 epidemic in China, according to a new study.
Article written by Gary Finnegan More than a third of medical staff suffered insomnia during the COVID-19 epidemic in China, according to a new study.
People with obsessive-compulsive disorder, or OCD, report that the severity of their symptoms was reduced by about half within four hours of smoking cannabis, according to a Washington… read more.
Article written by Christine Clark As politicians grapple with the idea of a lockdown or a more stringent lockdown GPs have called for an end to the ‘one-track’… read more.
Article written by Bruce Sylvester Dozens of the most widely used blood pressure medications show no tendency to elevate risk of depression, Danish researchers report.
Heart attack patients who are sarcastic or irritable could be putting their health at risk, according to research published today in the European Journal of Cardiovascular Nursing, a journal… read more.
Anxiety and depression are often linked and assumed to be closely related, but now research has shown for the first time that depression and anxiety have different biochemical… read more.
A drug used to treat cirrhosis of the liver may be an effective treatment for a form of Dementia and motorneuron disease, scientists have discovered. The research, led… read more.
An international team of doctors have developed a machine learning system which can predict the development of Bipolar Disorder up to 4 years before onset in young people:… read more.
Falls are the leading cause of fatal injuries in older adults, causing more than 800,000 hospitalizations and about 30,000 deaths in the U.S. every year. Some risk factors… read more.
Acadia Pharmaceuticals Inc. announced top-line results from its 298 patient Phase III CLARITY study which combined two identical, double-blind, placebo-controlled studies evaluating the efficacy, safety and tolerability of… read more.
Soleno Therapeutics, Inc. announced top-line results from the Company’s Phase III trial, DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for patients with Prader-Willi Syndrome… read more.
Axsome Therapeutics announced that AXS 05 (bupropion + dextromethorphan) met key secondary endpoints in the STRIDE-1 trial by rapidly and statistically significantly improving symptoms of depression on the… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.